Effect of postmenopausal hormone therapy on glucose and insulin concentrations

Diabetes Care

Volumn 21, Issue 10, 1998, Pages 1589-1595

  Espeland, Mark A ^a   Hogan, Patricia E ^a   Edwin Flneberg, S ^b   Howard, George ^a   Schrott, Helmutt ^c   Waclawiw, Myron A ^d   Bush, Trudy L ^e  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; GESTAGEN; GLUCOSE; INSULIN; MEDROXYPROGESTERONE; PLACEBO;

ADULT; ANALYTIC METHOD; ARTICLE; CARBOHYDRATE METABOLISM; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HORMONAL THERAPY; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL;

BLOOD GLUCOSE; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FASTING; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSULIN; MEDROXYPROGESTERONE 17-ACETATE; PLACEBOS; POSTMENOPAUSE; POSTPRANDIAL PERIOD; PROGESTERONE; PROGESTERONE CONGENERS; TIME FACTORS;

EID: 0031682105     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.21.10.1589     Document Type: Article

References (40)

1. Harris MI, Hadden WC, Knowler WC, Bennett PH: Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in U.S. population aged 20-74 yr. Diabetes 36:523-534, 1987
2. Stevenson JC: The metabolic and cardiovascular consequences of HRT. Br J Clin Pract 49:87-90, 1995
3. Barrett-Connor E, Laakso M: Ischemic heart disease in postmenopausal women: effects of estrogen use on glucose and insulin levels. Arteriosclerosis 10:531-534, 1990
4. Nabulsi AA, Folsom A, White A, Patsch W, Heiss G, Wu KK, Szklo M: Association of hormone-replacement therapy with various cardiovascular risk factors in postmenopausal women. N Engl J Med 328:1069-1975, 1993
5. Lindheim SR, Presser SC, Ditkoff EC, Vijod BS, Stanczyk FZ, Lobo RA: A possible bimodal effect of estrogen on insulin sensitivity in postmenopausal women and the attenuating effect of added progestin. Fertil Steril 60:664-667, 1993
6. Spellacy WN: Carbohydrate metabolism during treatment with estrogen, progestogen, and low-dose oral contraceptives. Am J Obstet Gynecol 142:732-734, 1982
7. O'Sullivan AJ, Ho KKY: A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women. J Clin Endocrinol Metab 80:1783-1788, 1985
8. Thorn M, Chakravarti S, Oram DH, Studd JWW: Effect of hormone replacement therapy on glucose and insulin tolerance in postmenopausal women. Brit J Obstet Gynecol 84:776-784, 1977
9. Wagner JD, Martino MA, Jayo MJ, Anthony MS, Clarkson TB, Cefalu WT: The effects of hormone replacement therapy on carbohydrate metabolism and cardiovascular risk factors in surgically postmenopausal cynomolgus monkeys. Metabolism 45:1-10, 1996
10. Larsson-Cohn U, Wallentin L: Metabolic and hormonal effects of post-menopausal oestrogen replacement treatment. Acta Endocrinol 86:583-596, 1977
11. Baskin DG, Gierke EP, Wilcox BJ, Matsumoto AM, Schwartz MW: Food intake and estradiol effects on insulin binding in brain and liver. Physiolog Behav 53:757-762, 1993
12. Godsland IF, Gangar K, Walton C, Gust MP, Whitehead MI, Wynn V, Stevenson JC: Insulin resistance, secretion, and elimination in postmenopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 42:846-853, 1993
13. Wilcox JG, Hwang JG, Hodis HN, Sevanian A, Stanczyk FZ, Loba RA: Cardioprotective effects of individual conjugated equine estrogens through their possible modulation of insulin resistance and oxidation of low-density lipoprotein. Fertil Steril 67:57-62, 1997
14. The Writing Group for the PEPI Trial: Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 273:199-208, 1995
15. Friedman LM, Furberg CD, DeMets DL: Fundamentals of Clinical Trials. 2nd ed. Littleton, MA, PSG Publishing, 1985
16. Espeland MA, Bush TL, Mebane-Sims I, Stefanick ML, Johnson S, Sherwin R, Waclawiw M: Rationale, design and conduct of the PEPI trial. Control Clin Trials 16:3S-19S, 1995
17. Wood PD, Kessler G, Lippel K, Stefanick ML, Wasilauskas CH, Wells HB: Physical and laboratory measurements in the PEPI trial. Control Gin Trials 16:36S-53S, 1995
18. Miller VT, Byington RL, Espeland MA, Langer R, Marcus R, Shumaker S, Stern MP: Baseline characteristics of the PEPI participants. Control Clin Trials 16:54S-65S, 1995
19. Johnson S, Mebane-Sims I, Hogan PE, Stoy DB. Recruitment of postmenopausal women in the PEPI trial. Control Clin Trials 16:20S-35S, 1995
20. Barrett-Connor E, Slone S, Greendale G, Kritz-Silverstein D, Espeland M, Johnson SR, Waclawiw M, Fineberg S: The Postmenopausal Estrogen/Progestin Interventions Study: primary outcomes in adherent women. Mauritas 27:261-274, 1997
21. Trinder P: Determination of glucose levels in blood using glucose oxidase with an alternative oxygen acceptor. Ann Clin Biochem 6:24-27, 1969
22. Morgan CR, Lazarow A: Immunoassay of insulin: two antibody system: plasma levels of normal, subdiabetic and diabetic rats. Diabetes 12:115-126, 1963
23. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 38:963-974, 1982
24. Jennrich RI, Schluchter MD: Unbalanced repeated measures models with structured covariance matrices. Biometrics 42:805-820, 1986
25. SAS/STAT Software: Changes and Enhancements, Release 6.06, Cary, NC, SAS Institute, 1992 (SAS tech. rep. P-229)
26. Little RJA, Rubin DB: Statistical Analysis With Missing Data. New York, Wiley, 1987
27. Little RJA: Modeling the drop-out mechanism in repeated-measures studies. J Am Stat Assoc 90:1112-1121, 1995
28. Walton C, Godsland IF, Proudler AJ, Wynn V, Stevenson JC: The effects of menopause on insulin sensitivity, secretion and elimination in nonobese healthy women. Euro J Clin Invest 23:466-473, 1993
29. Kumagai S, Holmang A, Bjorntorp P: The effects of oestrogen and progesterone on insulin in female rats. Acta Physiol Scand 149:91-97, 1993
30. Lindheim SR, Duffy DM, Kojima TK, Vijod MA, Stanczyk FZ, Lobo RA: The route of administration influences the effect of estrogen on insulin sensitivity in postmenopausal women, Fertil Steril 62:1176-1180, 1994
31. Andersson B, Mattsson L-A, Hahn L, Marin P, Lapidus L, Holm G, Bengtsson B-A, Bjorntorp P: Estrogen replacement therapy decreases hyperandrogenicity and improves glucose homeostasis and plasma lipids in postmenopausal women with non-insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82:638-643, 1997
32. Cagnacci A, Soldani R, Carriero PH, Paoletti AM, Fiorette P, Melis GB: Effects of low doses of transdermal 17B-estradiol on carbohydrate metabolism in postmenopausal women. J Clin Endocrinol Metab 74:1396-1400, 1992
33. Matute M, Kalkhoff RK: Sex steroid influences on hepatic glucogenesis and glycogen formulation. Endocrinology 92:762-768, 1973
34. DeCleyn K, Buyaert P, Coppens M: Carbohydrate metabolism during hormone substitution therapy. Mauritas 11:235-242, 1989
35. Spellacy W, Buhi W, Birk S: The effects of norgestrel on carbohydrate and lipid metabolism over one year. Am J Obstet Gynecol 125:984-986, 1976
36. Tuttle S, Turkington V: Effects of medroxy-progesterone acetate on carbohydrate metabolism. Obstet Gynecol 43:685-692, 1974
37. Sackett DL, Gent M: Controversy in counting and attributing events in clinical trials, N Engl J Med 301:1410-1412, 1979
38. Armitage P: Controversies and achievements in clinical trials. Control Clin Trials 5:67-72, 1984
39. Efron B, Feldman D: Compliance as an explanatory variable in clinical trials (with discussion). J Am Stat Assoc 86:9-26, 1991
40. Rochon J: Supplementing the intent-to-treat analysis: accounting for covariates observed postrandomization in clinical trials. J Am Stat Assoc 90:292-300, 1995